{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:19:09Z","timestamp":1793949549730,"version":"4.8.0"},"reference-count":215,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":196,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Heffter Research Institute"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1DA03889"],"award-info":[{"award-number":["RO1DA03889"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2018.05.012","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T12:24:26Z","timestamp":1528201466000},"page":"143-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":323,"special_numbering":"C","title":["The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act"],"prefix":"10.1016","volume":"142","author":[{"given":"Matthew W.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.05.012_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00223980.1956.9916206","article-title":"Lysergic acid diethylamide (LSD-25): XVII. Tolerance development and its relationship to a theory of psychosis","volume":"41","author":"Abramson","year":"1956","journal-title":"J.\u00a0Psychol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/02770906509106904","article-title":"Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects","volume":"3","author":"Abramson","year":"1965","journal-title":"J.\u00a0Asthma Res."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib3","first-page":"307","article-title":"Lysergic acid diethylamide (LSD-25) antagonists: chlorpromazine","volume":"1","author":"Abramson","year":"1960","journal-title":"J\u00a0Neuropsychiatr"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","article-title":"A\u00a0prehistoric mural in Spain depicting neurotropic Psilocybe Mushrooms?1","volume":"65","author":"Akers","year":"2011","journal-title":"Econ. Bot."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib5","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib6","series-title":"Pain Experts Predict Problems with Hydrocode Rescheduling","author":"Anson","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","article-title":"Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey","volume":"2","author":"Anthony","year":"1994","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0014-2999(89)90041-1","article-title":"Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline","volume":"159","author":"Appel","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00401404","article-title":"Tolerance and cross-tolerance among psychotomimetic drugs","volume":"13","author":"Appel","year":"1968","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib10","article-title":"Hallucinogens in drug discrimination","volume":"vol. 36","author":"Baker","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib11","series-title":"The Use of LSD in Psychotherapy and Alcoholism","first-page":"653","article-title":"On the action mechanisms of LSD 25","author":"Balestrieri","year":"1967"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib12","first-page":"394","article-title":"The regulation of psychedelic drugs","volume":"1","author":"Barrigar","year":"1964","journal-title":"The Psychedelic Review"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","article-title":"Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication","volume":"76","author":"Belleville","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0378-8741(82)90014-9","article-title":"Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer","volume":"5","author":"Bigwood","year":"1982","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib16","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212272","article-title":"Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function","volume":"4","author":"Blanchette","year":"2015","journal-title":"Drugs Context"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","article-title":"Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention","volume":"40","author":"Brandenburg","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib191","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/15563650802559632","article-title":"2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report","volume":"46","author":"Bronstein","year":"2008","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib192","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650903438566","article-title":"2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report","volume":"47","author":"Bronstein","year":"2009","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib193","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/15563650.2010.543906","article-title":"2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report","volume":"48","author":"Bronstein","year":"2010","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib194","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report","volume":"49","author":"Bronstein","year":"2011","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib195","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650.2012.746424","article-title":"2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report","volume":"50","author":"Bronstein","year":"2012","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib20","series-title":"Hallucinogens: Heaven and Hell","author":"British Psychological Society","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib21","article-title":"A\u00a0regulatory perspective on the evaluation of hallucinogen drugs for human use","author":"Calderon","year":"2017","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2018.05.012_bib203","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib23","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib24","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02791072.2013.825034","article-title":"Experienced drug users assess the relative harms and benefits of drugs: a web-based survey","volume":"45","author":"Carhart-Harris","year":"2013","journal-title":"J.\u00a0Psychoact. Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2018.05.012_bib26","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse","volume":"104","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib28","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","article-title":"Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB","volume":"31","author":"Carter","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1162\/089892905774597191","article-title":"Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors","volume":"17","author":"Carter","year":"2005","journal-title":"J.\u00a0Cognit. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"195","author":"Carter","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib31","series-title":"Alcohol Poisoning Deaths. Vital Signs","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib32","series-title":"Impaired Driving: Get the Facts. Motor Vehicle Safety","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib33","series-title":"Les champignons hallucinogenes du Mexique","first-page":"268","article-title":"Etude pharmacologique de la psilocybine","author":"Cerletti","year":"1958"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib34","series-title":"Rescheduling Hydrocodone Combination Products: Addressing the Abuse of America's Favorite Opioid","author":"Coleman","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib35","series-title":"A\u00a0History of Smoking","author":"Corti","year":"1931"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib36","series-title":"A\u00a0Brief History of Psychedelic Psychiatry","author":"Costandi","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.31887\/DCNS.2007.9.4\/macrocq","article-title":"Historical and cultural aspects of man's relationship with addictive drugs","volume":"9","author":"Crocq","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00690929","article-title":"Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD)","volume":"91","author":"Cunningham","year":"1987","journal-title":"Psychopharmacology (Berlin)"},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2018.05.012_bib39","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.drugalcdep.2009.08.011","article-title":"Monitoring risk: post marketing surveillance and signal detection","volume":"105","author":"Dart","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2018.05.012_bib40","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.drugalcdep.2009.05.019","article-title":"Signal detection in post-marketing surveillance for controlled substances","volume":"105","author":"Dasgupta","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2307\/278737","article-title":"Miniature mushroom stones from Guatemala","volume":"26","author":"de Borhegyi","year":"1961","journal-title":"Am. Antiq."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14737175.2016.1220834","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"de Veen","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib43","series-title":"Department of Justice","article-title":"LSD in the United States","author":"Drug Enforcement Administration","year":"1995"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib44","series-title":"Schedule of Controlled Substances: Proposed Rule: Rescheduling of Buprenorphine from Schedule V to Schedule III","first-page":"13114","author":"Drug Enforcement Administration","year":"2002"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib45","series-title":"Schedules of Controlled Substances: Placement of Perampanel into Schedule III","first-page":"62500","author":"Drug Enforcement Administration","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib46","series-title":"Schedules of Controlled Substances: Removal of Naloxegol from Control","first-page":"64349","author":"Drug Enforcement Administration","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib47","series-title":"Controlled Substances Act","author":"Drug Enforcement Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib48","series-title":"Schedules of Controlled Substances: Placement of FDA-approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (Delta-9-THC)] in Schedule II","first-page":"14815","author":"Drug Enforcement Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib210","series-title":"National Forensic Laboratory Information System (NFLIS) 2010 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib211","series-title":"National Forensic Laboratory Information System (NFLIS) 2011 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib212","series-title":"National Forensic Laboratory Information System (NFLIS) 2012 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib213","series-title":"National Forensic Laboratory Information System (NFLIS) 2013 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib214","series-title":"National Forensic Laboratory Information System (NFLIS) 2014 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib49","series-title":"National Forensic Laboratory Information System (NFLIS) 2015 Annual Report","author":"Drug Enforcement Administration Diversion Control Division","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib50","series-title":"The Psychedelic Explorer's Guide : Safe, Therapeutic, and Sacred Journeys","first-page":"336","author":"Fadiman","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(25)26118-3","article-title":"Methods for evaluating addiction liability. (A) \"Attitude\" of opiate addicts toward opiate-like drugs. (B) a short-term \"direct\" addiction test","volume":"133","author":"Fraser","year":"1961","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00952999309001618","article-title":"Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically","volume":"19","author":"Gable","year":"1993","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib55","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","article-title":"Comparison of acute lethal toxicity of commonly abused psychoactive substances","volume":"99","author":"Gable","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib57","series-title":"Global Drug Survey","author":"Global Drug Survey","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050860","article-title":"Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study","volume":"142","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib59","series-title":"Drug Regulation and Innovation : Empirical Evidence and Policy Options","first-page":"82","author":"Grabowski","year":"1976"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt1979255part1611","article-title":"Opioids: similarity between evaluations of subjective effects and animal self-administration results","volume":"25","author":"Griffiths","year":"1979","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib60","series-title":"Conference on Problems of Drug Dependence, Phoenix, Arizona","article-title":"The case for rescheduling psilocybin as a treatment medication: regulatory rationale, abuse liability, safety, and treatment efficacy","author":"Griffiths","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib62","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib63","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2018.05.012_bib64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/j.2326-1951.1981.tb01901.x","article-title":"LSD reconsidered","volume":"21","author":"Grinspoon","year":"1981","journal-title":"Sciences"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib67","series-title":"Psychedelic Drugs Reconsidered","first-page":"343","author":"Grinspoon","year":"1979"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib69","series-title":"Methods of Assessing the Reinforcing Properties of Abused Drugs","first-page":"489","article-title":"Addiction research center inventory (ARCI): measurement of euphoria and other drug effects","author":"Haertzen","year":"1987"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02584088","article-title":"Development of the addiction research center inventory (arci): selection of items that are sensitive to the effects of various drugs","volume":"4","author":"Haertzen","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib72","series-title":"Stimulus Properties of Drugs","first-page":"111","article-title":"An analysis of the function of drugs in the stimulus control of operant behavior","author":"Harris","year":"1971"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib73","series-title":"Untersuchungen zur Humanpharmakokinetik von Psilocybin","author":"Hasler","year":"1997"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib75","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neubiorev.2011.03.005","article-title":"5-HT receptors and reward-related behaviour: a review","volume":"35","author":"Hayes","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib77","series-title":"Heffter Research Institute","author":"Heffter Research Institute","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib79","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/0269881115598338","article-title":"Psilocybin, psychological distress, and suicidality","volume":"29","author":"Hendricks","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib80","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2018.05.012_bib81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","article-title":"The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research","volume":"35","author":"Henningfield","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib82","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1007\/s00213-016-4441-4","article-title":"Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research","volume":"233","author":"Henningfield","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02584089","article-title":"The addiction research center inventory: standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, Lsd-25, pyrahexyl and chlorpromazine","volume":"4","author":"Hill","year":"1963","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-3565(25)09716-2","article-title":"Studies on modification of the morphine abstinence syndrome by drugs","volume":"77","author":"Himmelsbach","year":"1943","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib84","series-title":"LSD, My Problem Child","first-page":"209","author":"Hofmann","year":"1980"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib85","first-page":"42","article-title":"Clinical, biochemical and psychologic effects of psilocybin","volume":"130","author":"Hollister","year":"1961","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib86","series-title":"Bestimmung Von Psilocybin-metaboliten Im Humanplasma Und Urin","author":"Holzmann","year":"1995"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib87","first-page":"40","article-title":"The effects of psilocybin on EEG and behaviour in monkeys","volume":"16","author":"Horibe","year":"1974","journal-title":"Act. Nerv. Super."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib88","series-title":"Interview with Albert Hofmann","author":"Horowitz","year":"1976"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib89","first-page":"1","article-title":"Trends in research on opiate addiction","volume":"24","author":"Isbell","year":"1956","journal-title":"Trans. Stud. Coll. Physicians Phila."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","article-title":"Comparison of the reactions induced by psilocybin and LSD-25 in man","volume":"1","author":"Isbell","year":"1959","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib91","series-title":"Psychopharmacology Frontiers","first-page":"362","article-title":"Effects of various drugs on the LSD reaction","author":"Isbell","year":"1959"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00403684","article-title":"A\u00a0comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC","volume":"14","author":"Isbell","year":"1969","journal-title":"Psychopharmacologia"},{"issue":"4","key":"10.1016\/j.neuropharm.2018.05.012_bib204","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archneurpsyc.1957.02330340026002","article-title":"Studies on the diethylamide of lysergic acid (LSD-25). II. Effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSD-reaction","volume":"77","author":"Isbell","year":"1957","journal-title":"AMA Arch. Neurol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00407974","article-title":"Cross tolerance between LSD and psilocybin","volume":"2","author":"Isbell","year":"1961","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib94","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0091-3057(80)90279-8","article-title":"LDS-25 as a discriminative stimulus for response selection by pigeons","volume":"13","author":"Jarbe","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib226","series-title":"Drug Addiction I: Morphine, Sedative\/Hypnotic and Alcohol Dependence","first-page":"197","article-title":"Assessment of the abuse potentiality of morphinelike drugs (Methods Used in Man)","author":"Jasinski","year":"1977"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib95","series-title":"Testing for Abuse Liability of Drugs in Humans","first-page":"73","article-title":"Human abuse liability assessment by measurement of subjective and phsyiological effects","author":"Jasinski","year":"1989"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib96","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0165-6147(84)90415-2","article-title":"Abuse liability assessment in human subjects","volume":"5","author":"Jasinski","year":"1984","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib97","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1037\/1064-1297.8.2.163","article-title":"Active cocaine immunization attenuates the discriminative properties of cocaine","volume":"8","author":"Johnson","year":"2000","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib98","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib99","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib101","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1037\/a0031692","article-title":"Comparative abuse liability of GHB and ethanol in humans","volume":"21","author":"Johnson","year":"2013","journal-title":"Exp. Clin. Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib102","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib103","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers","volume":"123","author":"Johnson","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib104","series-title":"A\u00a0Brief History of Microdosing","author":"Koebler","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00435266","article-title":"Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens","volume":"76","author":"Koerner","year":"1982","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib106","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib107","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib108","series-title":"Neurobiology of Addiction","first-page":"490","author":"Koob","year":"2006"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00421458","article-title":"An analysis of some discriminative properties of d-amphetamine","volume":"39","author":"Kuhn","year":"1974","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib110","series-title":"Acid Dreams : the Complete Social History of LSD : the CIA, the Sixties, and beyond","author":"Lee","year":"1992"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib111","series-title":"Phantastica : a Classic Survey on the Use and Abuse of Mind-altering Plants","first-page":"288","author":"Lewin","year":"1998"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib112","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1445-5994.2012.02955.x","article-title":"A\u00a0fatal case of 'magic mushroom' ingestion in a heart transplant recipient","volume":"42","author":"Lim","year":"2012","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/00275514.1971.12019194","article-title":"New records of mushroom stones from Guatemala","volume":"63","author":"Lowy","year":"1971","journal-title":"Mycologia"},{"issue":"11","key":"10.1016\/j.neuropharm.2018.05.012_bib114","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib115","series-title":"Why Power Women Are Micro-dosing LSD at Work","author":"Malone","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib116","first-page":"146","article-title":"Assessment of the abuse potentiality of amphetamines and LSD-like hallucinogens in man and its relationship to basic animal assessment programs","author":"Martin","year":"1973","journal-title":"Psychic"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2492\/inflammregen.29.47","article-title":"Historical overview of psychoactive mushrooms","volume":"29","author":"Matsushima","year":"2009","journal-title":"Inflamm. Regen."},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2018.05.012_bib118","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.drugalcdep.2009.08.003","article-title":"Case histories in pharmaceutical risk management","volume":"105","author":"McCormick","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib196","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3109\/15563650.2013.863906","article-title":"2012 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th annual report","volume":"51","author":"Mowry","year":"2013","journal-title":"Clin. Toxicol (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib197","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3109\/15563650.2014.987397","article-title":"2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report","volume":"52","author":"Mowry","year":"2014","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib198","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/15563650.2015.1102927","article-title":"2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report","volume":"53","author":"Mowry","year":"2015","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib199","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/15563650.2016.1245421","article-title":"2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report","volume":"54","author":"Mowry","year":"2016","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib209","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib119","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881109106915","article-title":"Harms associated with psychoactive substances: findings of the UK National Drug Survey","volume":"24","author":"Morgan","year":"2010","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib120","series-title":"Alcohol Facts and Statistics","author":"National Institute on Alcohol Abuse and Alcoholism","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib121","series-title":"Understanding Drug Use and Addiction","author":"National Institute on Drug Abuse","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib122","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib123","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1086\/383628","article-title":"LSD before Leary. Sidney Cohen's critique of 1950s psychedelic drug research","volume":"88","author":"Novak","year":"1997","journal-title":"Isis"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002047","article-title":"Illegal drugs laws: clearing a 50-year-old obstacle to research","volume":"13","author":"Nutt","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib126","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib127","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib128","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib129","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","first-page":"649","article-title":"Drug addiction","author":"O'Brien","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib131","series-title":"The Rise and Fall of LSD. Los Angeles Review of Books","author":"Penner","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib132","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2014.0873","article-title":"Homological scaffolds of brain functional networks","volume":"11","author":"Petri","year":"2014","journal-title":"J.\u00a0R. Soc. Interface"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib133","series-title":"Assessment of Kratom under the CSA Eight Factors and Scheduling Recommendation","author":"Pinney Associates","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib134","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib135","series-title":"The Trip Treatment","author":"Pollan","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib136","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib137","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","author":"Roseman","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib138","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib139","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","author":"Rucker","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.aap.2014.04.003","article-title":"Trends in drug use among drivers killed in U.S. traffic crashes, 1999-2010","volume":"70","author":"Rudisill","year":"2014","journal-title":"Accid. Anal. Prev."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib141","series-title":"An Inquiry into the Effects of Ardent Spirits upon the Human Body and Mind : with an Account of the Means of Preventing, and of the Remedies for Curing Them","first-page":"50","author":"Rush","year":"1808"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib142","first-page":"69","article-title":"The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 B.P.)","volume":"2","author":"Samorini","year":"1992","journal-title":"Integration"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib143","doi-asserted-by":"crossref","first-page":"46421","DOI":"10.1038\/srep46421","article-title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin","volume":"7","author":"Schartner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib144","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00422707","article-title":"Lysergic acid diethylamide (LSD) as a discriminative cue: drugs with similar stimulus properties","volume":"26","author":"Schechter","year":"1972","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib146","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.163.3864.245","article-title":"Hallucinogens of plant origin","volume":"163","author":"Schultes","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib147","series-title":"Plants of the Gods : Their Sacred, Healing, and Hallucinogenic Powers","first-page":"208","author":"Schultes","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib148","series-title":"End the Ban on Psychoactive Drug Research","author":"Scientific American Editors","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib149","article-title":"Studies with psychedelic drugs in human volunteers","author":"Sellers","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.114.148031","article-title":"Can psychedelic compounds play a part in drug dependence therapy?","volume":"206","author":"Sessa","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib151","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib152","series-title":"The History and Development of the Leading International Drug Control Conventions","author":"Sinha","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib153","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2004.04.011","article-title":"Debating the controlled substances act","volume":"76","author":"Spillane","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib227","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0006-3223(95)00418-1","article-title":"Increased activation of indirect semantic associations under psilocybin","volume":"39","author":"Spitzer","year":"1996","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib154","series-title":"Psilocybin Mushrooms of the World : an Identification Guide","first-page":"245","author":"Stamets","year":"1996"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib155","series-title":"Storming Heaven: LSD and the American Dream","first-page":"396","author":"Stevens","year":"1987"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib208","series-title":"DMT : The Spirit Molecule : A Doctor's Revolutionary Research Into the Biology of Near-Death And Mystical Experiences","author":"Strassman","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib158","series-title":"Dug Abuse Warning Network, 2011: Selected Tables\u00a0of National Estimates of Drug-related Emergency Department Visits","author":"Substance Abuse and Mental Health Services Administration","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib159","series-title":"Client Level Data\/TEDS","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib160","series-title":"Population Data\/NSDUH","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib161","series-title":"The Opium Problem","author":"Terry","year":"1970"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib162","first-page":"11","article-title":"A\u00a0new indication for gamma hydroxybutyrate (xyrem) for narcolepsy","volume":"48","author":"The Medical Letter","year":"2006","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib163","first-page":"33","article-title":"The forgotten mushrooms of ancient Peru. Global mountain action","volume":"1","author":"Truttman","year":"2012","journal-title":"Fungi and Mountains Publication Series"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib164","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: a re-emerging therapeutic paradigm","volume":"187","author":"Tupper","year":"2015","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib165","series-title":"Family Smoking Prevention and Tobacco Control Act","author":"U.S. Congress","year":"2009"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib166","series-title":"Improving Regulatory Transparency for New Medical Therapies Act","author":"U.S. Congress","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib167","series-title":"U.S. Department of Health and Human Services","first-page":"44396","article-title":"Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents","author":"U.S. Food and Drug Administration","year":"1996"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib168","series-title":"U.S. Department of Health and Human Services","article-title":"PDUFA reauthorization performance goals and procedures fiscal years 2013 through 2017","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib169","series-title":"U.S. Department of Health and Human Services","article-title":"Risk evaluation and mitigation strategies: modifications and revisions: guidance for industry","author":"U.S. Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib170","series-title":"U.S. Department of Health and Human Services","article-title":"Assessment of abuse potential of drugs: guidance for industry","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib171","series-title":"Benefit-risk Assessments in Drug Regulatory Decision-making; Public Meeting; Request for Comments","first-page":"37230","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib172","series-title":"Development & Approval Process (Drugs)","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib173","series-title":"Labeling","first-page":"21","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib174","series-title":"A\u00a0Guide to the Rulemaking Process","author":"U.S. Office of the Federal Register","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib175","series-title":"Usona Institute","author":"Usona Institute","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib176","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms","volume":"29","author":"van Amsterdam","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib177","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000317249","article-title":"Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population","volume":"16","author":"van Amsterdam","year":"2010","journal-title":"Eur. Addiction Res."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib178","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"van Amsterdam","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib179","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF01923013","article-title":"Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test","volume":"34","author":"Van Went","year":"1978","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib180","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib207","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib181","series-title":"A\u00a0Really Good Day : How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life","first-page":"229","author":"Waldman","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib182","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881116642538","article-title":"Hallucinogen use and intimate partner violence: prospective evidence consistent with protective effects among men with histories of problematic substance use","volume":"30","author":"Walsh","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib183","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","article-title":"Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion","volume":"5","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Sleep Med"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib228","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.2164-0947.1959.tb00681.x","article-title":"The hallucinogenic mushrooms of Mexico: an adventure in enthomycological exploration","volume":"21","author":"Wasson","year":"1959","journal-title":"Trans. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib201","series-title":"Mushrooms, Russia, and History","author":"Wasson","year":"1957"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib184","series-title":"Professor Was Injected with Magic Mushrooms to Have 'near Death Experience'","author":"Waugh","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib185","first-page":"73","article-title":"On the nature of addiction and habituation","volume":"57","author":"Wikler","year":"1961","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib186","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.pbb.2007.06.003","article-title":"Psilocybin-induced stimulus control in the rat","volume":"87","author":"Winter","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.012_bib187","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib188","article-title":"How will DEA affect your clinical study?","volume":"7","author":"Woodworth","year":"2011","journal-title":"Journal of Clinical Research Best Practices"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib189","series-title":"ICD-10 Classification of Mental and Behavioural Disorders (The): Diagnostic Criteria for Research","author":"World Health Organization","year":"1993"},{"key":"10.1016\/j.neuropharm.2018.05.012_bib190","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.clinthera.2016.11.007","article-title":"The US food and drug Administration's risk evaluation and mitigation strategy (REMS) program - current status and future direction","volume":"38","author":"Wu","year":"2016","journal-title":"Clin. Therapeut."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:51:34Z","timestamp":1758437494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818302296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":215,"alternative-id":["S0028390818302296"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}